hdac8in1

MDK-7933 (HDAC8-IN-1) is a HDAC8 inhibitor with an IC50 of 27.2 nM in cancer cell lines. MDK-7933 shows antiproliferative effects toward several human lung cancer cell lines (A549, H1299, and CL1-5). HDAC8-IN-1 exhibits cytotoxicity against human lung CL1-5 cells without significant cytotoxicity for normal IMR-90 cells[1].

HDAC8-IN-12 (compound 5k), a non-hydroxamic acid derivative, serves as a selective HDAC8 inhibitor with an IC 50 of 0.12 nM and demonstrates potent efficacy against breast cancer. This compound enhances anti-tumor immunity by activating T cells, elevating M1 macrophage levels, and reducing M2 macrophage proportions. In an orthotopic mouse model of breast cancer, HDAC8-IN-12, administered at 50 mg/kg, effectively suppresses tumor growth.

HDAC8-IN-14 is a curcumin derivative serving as a selective HDAC8 inhibitor with a Ki of 9 nM. It induces reactive oxygen species (ROS) production, disrupts mitochondrial membrane potential, and promotes apoptosis. Furthermore, HDAC8-IN-14 significantly triggers cell accumulation in the sub-G0/G1 phase, indicative of apoptosis or necroptosis. It upregulates cytochrome c, cleaved caspase-3, and pro-apoptotic protein Bak expression, while maintaining anti-apoptotic protein Bcl-2 levels unchanged, making it a valuable compound for leukemia research.

HDAC8-IN-11 is a PROTAC target protein ligand.

HDAC8-IN-10 (compound 15) serves as a potent inhibitor of HDAC8, exhibiting an IC50 value of 7.6 nM. It also acts as a ligand for the HDAC8 target protein, utilized in the synthesis of PROTAC YX862.